Immunostimulation by synthetic lipopeptide-based vaccine candidates: Structure-activity relationships

Frontiers in Immunology

Volumn 4, Issue OCT, 2013, Pages

  Zaman, Mehfuz ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Lipopeptide; Peptide; Self adjuvanting; Toll like receptor; Vaccine

Indexed keywords

ADJUVANT; LIPOPEPTIDE; PALMITIC ACID; PATTERN RECOGNITION RECEPTOR; PEPTIDE VACCINE; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 2;

CELL PROLIFERATION; CRYSTAL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; DIMERIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MITOGENICITY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; VACCINATION;

EID: 84885394756     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00318     Document Type: Review

References (114)

1. Hefti K, David G. Safe handling of vaccines: the rewards of rigorous routines. S D Med (2013) Spec no:119-22.
2. Rueckert C, Guzman CA. Vaccines: from empirical development to rational design. PLoS Pathog (2012) 8:e1003001. doi:10.1371/journal.ppat.1003001.
3. Wang G, Cao RY, Chen R, Mo L, Han JF, Wang X, et al. Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions. Proc Natl Acad Sci U S A (2013) 110:7619-24. doi:10.1073/pnas.1300233110.
4. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood (2008) 112:1557-69. doi:10.1182/blood-2008-05-078154.
5. Giuntoli RL II, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res (2002) 8:922-31.
6. Yin L, Calvo-Calle JM, Cruz J, Newman FK, Frey SE, Ennis FA, et al. CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans. J Immunol (2013) 190: 6023-33. doi:10.4049/jimmunol.1202523.
7. Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, et al. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol (2013) 190:6221-9. doi:10.4049/jimmunol.1202654.
8. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol (2011) 11:865-72. doi:10.1038/nri3085.
9. Gururajan M, Jacob J, Pulendran B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One (2007) 2:e863. doi:10.1371/journal.pone.0000863.
10. MacLeod H, Wetzler LM. T cell activation by TLRs: a role for TLRs in the adaptive immune response. Sci STKE (2007) 2007:e48. doi:10.1126/stke.4022007pe48.
11. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 168:4531-7.
12. Kokkinopoulos I, Jordan WJ, Ritter MA. Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes. Mol Immunol (2005) 42:957-68. doi:10.1016/j.molimm.2004.09.037.
13. Carta S, Silvestri M, Rossi GA. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Ital J Pediatr (2013) 39:29. doi:10.1186/1824-7288-39-29.
14. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol (2007) 7:353-64. doi:10.1038/nri2079.
15. Takeda K, Akira S. TLR signaling pathways. Semin Immunol (2004) 16:3-9. doi:10.1016/j.smim.2003.10.003.
16. Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A. Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines (2011) 10:1053-61. doi:10.1586/erv.11.48.
17. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol (2009) 21:317-37. doi:10.1093/intimm/dxp017.
18. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med (2007) 13:460-9. doi:10.1016/j.molmed.2007.09.002.
19. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci (2002) 27:474-82. doi:10.1016/S0968-0004(02)02145-X.
20. Lundberg AM, Ketelhuth DF, Johansson ME, Gerdes N, Liu S, Yamamoto M, et al. Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc Res (2013) 99:364-73. doi:10.1093/cvr/cvt033.
21. Fitzgerald KA, Palsson-Mcdermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature (2001) 413:78-83. doi:10.1038/35092578.
22. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest (2003) 111:1571-8. doi:10.1172/JCI17573.
23. O'Neill LA, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol (2003) 24:286-90. doi:10.1016/S1471-4906(03)00115-7.
24. Brikos C, O'Neill LA. Signalling of toll-like receptors. Handb Exp Pharmacol (2008) 183:21-50. doi:10.1007/978-3-540-72167-3_2.
25. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science (1999) 285:732-6. doi:10.1126/science.285.5428.732.
26. Dalpke A, Frank J, Peter M, Heeg K. Activation of toll-like receptor 9 by DNA from different bacterial species. Infect Immun (2006) 74:940-6. doi:10.1128/IAI.74.2.940-946.2006.
27. Huang LY, Dumontelle JL, Zolodz M, Deora A, Mozier NM, Golding B. Use of toll-like receptor assays to detect and identify microbial contaminants in biological products. J Clin Microbiol (2009) 47:3427-34. doi:10.1128/JCM.00373-09.
28. Wang J, Shao Y, Bennett TA, Shankar RA, Wightman PD, Reddy LG. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J Biol Chem (2006) 281:37427-34. doi:10.1074/jbc.M605311200.
29. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol (2013) 13:453-60. doi:10.1038/nri3446.
30. Shen Y, Kawamura I, Nomura T, Tsuchiya K, Hara H, Dewamitta SR, et al. Toll-like receptor 2-and MyD88-dependent phosphatidylinositol 3-kinase and Rac1 activation facilitates the phagocytosis of Listeria monocytogenes by murine macrophages. Infect Immun (2010) 78:2857-67. doi:10.1128/IAI.01138-09.
31. Dunn-Siegrist I, Tissieres P, Drifte G, Bauer J, Moutel S, Pugin J. Toll-like receptor activation of human cells by synthetic triacylated lipid A-like molecules. J Biol Chem (2012) 287:16121-31. doi:10.1074/jbc.M112.348383.
32. Shah P, Fatehchand K, Patel H, Fang H, Justiniano SE, Mo X, et al. Toll-like receptor 2 ligands regulate monocyte Fcgamma receptor expression and function. J Biol Chem (2013) 288:12345-52. doi:10.1074/jbc.M113.449983.
33. Triantafilou M, Manukyan M, Mackie A, Morath S, Hartung T, Heine H, et al. Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent. J Biol Chem (2004) 279:40882-9. doi:10.1074/jbc.M400466200.
34. Gillrie MR, Zbytnuik L, Mcavoy E, Kapadia R, Lee K, Waterhouse CC, et al. Divergent roles of Toll-like receptor 2 in response to lipoteichoic acid and Staphylococcus aureus in vivo. Eur J Immunol (2010) 40:1639-50. doi:10.1002/eji.200939929.
35. Gisch N, Kohler T, Ulmer AJ, Muthing J, Pribyl T, Fischer K, et al. Structural reevaluation of Streptococcus pneumoniae Lipoteichoic acid and new insights into its immunostimulatory potency. J Biol Chem (2013) 288:15654-67. doi:10.1074/jbc.M112.446963.
36. Sato M, Sano H, Iwaki D, Kudo K, Konishi M, Takahashi H, et al. Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. J Immunol (2003) 171:417-25.
37. Guerrero AT, Cunha TM, Verri WA Jr., Gazzinelli RT, Teixeira MM, Cunha FQ, et al. Toll-like receptor 2/MyD88 signaling mediates zymosan-induced joint hypernociception in mice: participation of TNF-alpha, IL-1beta and CXCL1/KC. Eur J Pharmacol (2012) 674:51-7. doi:10.1016/j.ejphar.2011.10.023.
38. Aliprantis AO, Weiss DS, Radolf JD, Zychlinsky A. Release of Toll-like receptor-2-activating bacterial lipoproteins in Shigella flexneri culture supernatants. Infect Immun (2001) 69:6248-55. doi:10.1128/IAI.69.10.6248-6255.2001.
39. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity (2009) 31:873-84. doi:10.1016/j.immuni.2009.09.018.
40. Turner JD, Langley RS, Johnston KL, Gentil K, Ford L, Wu B, et al. Wolbachia lipoprotein stimulates innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of filariasis. J Biol Chem (2009) 284:22364-78. doi:10.1074/jbc.M901528200.
41. Dziarski R, Gupta D. Staphylococcus aureus peptidoglycan is a toll-like receptor 2 activator: a reevaluation. Infect Immun (2005) 73:5212-6. doi:10.1128/IAI.73.8.5212-5216.2005.
42. Zhu X, Bagchi A, Zhao H, Kirschning CJ, Hajjar RJ, Chao W, et al. Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med (2007) 35:886-92. doi:10.1097/01.CCM.0000256723.37586.A2.
43. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep (2004) 5:1000-6. doi:10.1038/sj.embor.7400248.
44. Raaijmakers JM, De Bruijn I, Nybroe O, Ongena M. Natural functions of lipopeptides from Bacillus and Pseudomonas: more than surfactants and antibiotics. FEMS Microbiol Rev (2010) 34:1037-62. doi:10.1111/j.1574-6976.2010.00221.x.
45. Zom GG, Khan S, Filippov DV, Ossendorp F. TLR ligand-peptide conjugate vaccines: toward clinical application. Adv Immunol (2012) 114:177-201. doi:10.1016/B978-0-12-396548-6.00007-X.
46. Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, Mages J, et al. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol (2008) 83:692-701. doi:10.1189/jlb.0807586.
47. Mandal SM, Barbosa AE, Franco OL. Lipopeptides in microbial infection control: scope and reality for industry. Biotechnol Adv (2013) 31:338-45. doi:10.1016/j.biotechadv.2013.01.004.
48. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother (2005) 55:283-8. doi:10.1093/jac/dkh546.
49. Makovitzki A, Avrahami D, Shai Y. Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci U S A (2006) 103:15997-6002. doi:10.1073/pnas.0606129103.
50. Kanlayavattanakul M, Lourith N. Lipopeptides in cosmetics. Int J Cosmet Sci (2010) 32:1-8. doi:10.1111/j.1468-2494.2009.00543.x.
51. Morikawa M, Daido H, Takao T, Murata S, Shimonishi Y, Imanaka T. A new lipopeptide biosurfactant produced by Arthrobacter sp. strain MIS38. J Bacteriol (1993) 175:6459-66.
52. Seghal Kiran G, Anto Thomas T, Selvin J, Sabarathnam B, Lipton AP. Optimization and characterization of a new lipopeptide biosurfactant produced by marine Brevibacterium aureum MSA13 in solid state culture. Bioresour Technol (2010) 101:2389-96. doi:10.1016/j.biortech.2009.11.023.
53. de Sousa T, Bhosle S. Isolation and characterization of a lipopeptide bioemulsifier produced by Pseudomonas nitroreducens TSB.MJ10 isolated from a mangrove ecosystem. Bioresour Technol (2012) 123:256-62. doi:10.1016/j.biortech.2012.07.056.
54. Vollenbroich D, Ozel M, Vater J, Kamp RM, Pauli G. Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis. Biologicals (1997) 25:289-97. doi:10.1006/biol.1997.0099.
55. Matz C, Kjelleberg S. Off the hook-how bacteria survive protozoan grazing. Trends Microbiol (2005) 13:302-7. doi:10.1016/j.tim.2005.05.009.
56. Julkowska D, Obuchowski M, Holland IB, Seror SJ. Comparative analysis of the development of swarming communities of Bacillus subtilis 168 and a natural wild type: critical effects of surfactin and the composition of the medium. J Bacteriol (2005) 187:65-76. doi:10.1128/JB.187.1.65-76.2005.
57. Neu TR. Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. Microbiol Rev (1996) 60:151-66.
58. Hopp TP. Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugation to a fatty acid carrier. Mol Immunol (1984) 21:13-6. doi:10.1016/0161-5890(84)90084-1.
59. Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem (2008) 15:506-16. doi:10.2174/092986708783503249.
60. Loing E, Andrieu M, Thiam K, Schorner D, Wiesmuller KH, Hosmalin A, et al. Extension of HLA-A*0201-restricted minimal epitope by N epsilon-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells. J Immunol (2000) 164:900-7.
61. Thiam K, Loing E, Verwaerde C, Auriault C, Gras-Masse H. IFN-gamma-derived lipopeptides: influence of lipid modification on the conformation and the ability to induce MHC class II expression on murine and human cells. J Med Chem (1999) 42:3732-6. doi:10.1021/jm991025f.
62. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (1989) 342:561-4. doi:10.1038/342561a0.
63. Borges E, Wiesmuller KH, Jung G, Walden P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J Immunol Methods (1994) 173:253-63. doi:10.1016/0022-1759(94)90304-2.
64. Khan S, Weterings JJ, Britten CM, De Jong AR, Graafland D, Melief CJ, et al. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol Immunol (2009) 46:1084-91. doi:10.1016/j.molimm.2008.10.006.
65. Reichel F, Roelofsen AM, Geurts HP, Van Der Gaast SJ, Feiters MC, Boons GJ. Synthesis and supramolecular characterization of a novel class of glycopyranosyl-containing amphiphiles. J Org Chem (2000) 65:3357-66. doi:10.1021/jo991685s.
66. Spohn R, Buwitt-Beckmann U, Brock R, Jung G, Ulmer AJ, Wiesmuller KH. Synthetic lipopeptide adjuvants and Toll-like receptor 2-structure-activity relationships. Vaccine (2004) 22:2494-9. doi:10.1016/j.vaccine.2003.11.074.
67. Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Ulmer AJ. Lipopeptide structure determines TLR2 dependent cell activation level. FEBS J (2005) 272:6354-64. doi:10.1111/j.1742-4658.2005.05029.x.
68. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 101:15440-5. doi:10.1073/pnas.0406740101.
69. Hubschle T, Mutze J, Muhlradt PF, Korte S, Gerstberger R, Roth J. Pyrexia, anorexia, adipsia, and depressed motor activity in rats during systemic inflammation induced by the Toll-like receptors-2 and -6 agonists MALP-2 and FSL-1. Am J Physiol Regul Integr Comp Physiol (2006) 290: R180-7. doi:10.1152/ajpregu.00579.2005.
70. Chandran SS, Verhoeven D, Teijaro JR, Fenton MJ, Farber DL. TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses. J Immunol (2009) 183:7832-41. doi:10.4049/jimmunol.0901683.
71. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol (2002) 169:4905-12.
72. Metzger JW, Beck-Sickinger AG, Loleit M, Eckert M, Bessler WG, Jung G. Synthetic S-(2,3-dihydroxypropyl)-cysteinyl peptides derived from the N-terminus of the cytochrome subunit of the photoreaction centre of Rhodopseudomonas viridis enhance murine splenocyte proliferation. J Pept Sci (1995) 1:184-90. doi:10.1002/psc.310010305.
73. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med (1997) 185:1951-8. doi:10.1084/jem.185.11.1951.
74. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect Immun (1998) 66:4804-10.
75. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, et al. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2-and MyD88-dependent signaling pathway. J Immunol (2000) 164:554-7.
76. Morr M, Takeuchi O, Akira S, Simon MM, Muhlradt PF. Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol (2002) 32:3337-47. doi:10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I.
77. Seyberth T, Voss S, Brock R, Wiesmuller KH, Jung G. Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships. J Med Chem (2006) 49:1754-65. doi:10.1021/jm050585d.
78. Schromm AB, Howe J, Ulmer AJ, Wiesmuller KH, Seyberth T, Jung G, et al. Physicochemical and biological analysis of synthetic bacterial lipopeptides: validity of the concept of endotoxic conformation. J Biol Chem (2007) 282:11030-7. doi:10.1074/jbc.M700287200.
79. Chua BY, Zeng W, Lau YF, Jackson DC. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine (2007) 25:92-101. doi:10.1016/j.vaccine.2006.07.012.
80. Agnihotri G, Crall BM, Lewis TC, Day TP, Balakrishna R, Warshakoon HJ, et al. Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides. J Med Chem (2011) 54:8148-60. doi:10.1021/jm201071e.
81. Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol (2007) 179:2187-94.
82. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A (2004) 101:3029-34. doi:10.1073/pnas.0400171101.
83. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell (2007) 130:1071-82. doi:10.1016/j.cell.2007.09.008.
84. Robinson JH, Case MC, Brooks CG. Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells. Immunology (1992) 76:593-8.
85. Bueno C, Lee KK, Chau LA, Lee-Chan E, Singh B, Strejan GH, et al. Mechanism of modulation of T cell responses by N-palmitoylated peptides. Eur J Immunol (2004) 34:3497-507. doi:10.1002/eji.200425369.
86. Bomford R. The adjuvant activity of fatty acid esters. The role of acyl chain length and degree of saturation. Immunology (1981) 44:187-92.
87. Gahery-Segard H, Pialoux G, Figueiredo S, Igea C, Surenaud M, Gaston J, et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol (2003) 77:11220-31. doi:10.1128/JVI.77.20.11220-11231.2003.
88. Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, et al. Multiepitopic B-and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol (2000) 74:1694-703. doi:10.1128/JVI.74.4.1694-1703.2000.
89. BenMohamed L, Thomas A, Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect Immun (2004) 72:4376-84. doi:10.1128/IAI.72.8.4376-4384.2004.
90. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med (2000) 6:1258-63. doi:10.1038/81366.
91. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood (1997) 90:1751-67.
92. Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, Sakabetis E, et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol (2002) 76:4212-21. doi:10.1128/JVI.76.9.4212-4221.2002.
93. Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol (1997) 159:1383-92.
94. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol (1997) 27:1242-53. doi:10.1002/eji.1830270528.
95. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, Lafond R, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 95:341-9. doi:10.1172/JCI117662.
96. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis (2002) 2:425-31. doi:10.1016/S1473-3099(02)00318-3.
97. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol (2009) 2:129-43. doi:10.1038/mi.2008.81.
98. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology (2002) 106:113-21. doi:10.1046/j.1365-2567.2002.01396.x.
99. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, Benmohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol (2004) 34:3102-14. doi:10.1002/eji.200425166.
100. Toth I. A novel chemical approach to drug delivery: lipidic amino acid conjugates. J Drug Target (1994) 2:217-39. doi:10.3109/10611869408996805.
101. Skwarczynski M, Toth I. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. Methods Mol Biol (2011) 751:297-308. doi:10.1007/978-1-61779-151-2_18.
102. Zhong G, Toth I, Reid R, Brunham RC. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis. J Immunol (1993) 151:3728-36.
103. Horvath A, Olive C, Wong A, Clair T, Yarwood P, Good M, et al. Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes. J Med Chem (2002) 45:1387-90. doi:10.1021/jm0110441.
104. Moyle PM, Olive C, Ho MF, Good MF, Toth I. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem (2006) 49:6364-70. doi:10.1021/jm060475m.
105. Hayman WA, Toth I, Flinn N, Scanlon M, Good MF. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol (2002) 80:178-87. doi:10.1046/j.1440-1711.2002.01067.x.
106. Abdel-Aal AB, Batzloff MR, Fujita Y, Barozzi N, Faria A, Simerska P, et al. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem (2008) 51:167-72. doi:10.1021/jm701091d.
107. Abdel-Aal AB, Zaman M, Fujita Y, Batzloff MR, Good MF, Toth I. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. J Med Chem (2010) 53:8041-6. doi:10.1021/jm1007787.
108. Abdel-Aal AB, El-Naggar D, Zaman M, Batzloff M, Toth I. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand. J Med Chem (2012) 55:6968-74. doi:10.1021/jm300822g.
109. Apte SH, Groves PL, Skwarczynski M, Fujita Y, Chang C, Toth I, et al. Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model. PLoS One (2012) 7:e40928. doi:10.1371/journal.pone.0040928.
110. Zaman M, Abdel-Aal AB, Fujita Y, Phillipps KS, Batzloff MR, Good MF, et al. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship. PLoS One (2012) 7:e30146. doi:10.1371/journal.pone.0030146.
111. Zaman M, Abdel-Aal AB, Fujita Y, Ziora ZM, Batzloff MR, Good MF, et al. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes. J Med Chem (2012) 55:8515-23. doi:10.1021/jm301074n.
112. Abdel-Aal AB, Al-Isae K, Zaman M, Toth I. Simple synthetic toll-like receptor 2 ligands. Bioorg Med Chem Lett (2011) 21:5863-5. doi:10.1016/j.bmcl.2011.07.102.
113. Zaman M, Abdel-Aal AB, Phillipps KS, Fujita Y, Good MF, Toth I. Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine (2010) 28:2243-8. doi:10.1016/j.vaccine.2009.12.046.
114. Phillipps KS, Wykes MN, Liu XQ, Brown M, Blanchfield J, Toth I. A novel synthetic adjuvant enhances dendritic cell function. Immunology (2009) 128:e582-8. doi:10.1111/j.1365-2567.2008.03038.x.